Type 1 diabetes with other specified/multiple/unspecified complications

MESH PheWeb

E4_DM1NASCOMP

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Hospital Discharge: ICD-10 E10.6, E10.6+M14.2, E10.6+M14.6, E10.7, E10.8

Hospital discharge: ICD-9 2507B|2508B

Hospital discharge: ICD-8 $!$

Cause of death: ICD-10 E10.6, E10.6+M14.2, E10.6+M14.6, E10.7, E10.8

Cause of death: ICD-9 2507B|2508B

Cause of death: ICD-8 $!$

KELA reimbursements: KELA codes ANY

KELA reimbursements: ICD-10 E10

164170

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

5189

Check minimum number of events None

5189

Include endpoints None

5189

E4_DM1NASCOMP

Extra metadata

Level in the ICD hierarchy 4

First used in FinnGen datafreeze DF3

Similar endpoints

↥

List of similar endpoints to Type 1 diabetes with other specified/multiple/unspecified complications based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	5055	2421	2634
Unadjusted prevalence (%)	1.64	1.40	1.95
Mean age at first event (years)	36.71	34.83	38.43

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.06	5.18 [3.39, 7.93]	3.5e-14	519
15 years	0.02	3.30 [2.31, 4.72]	6.3e-11	239
5 years	0.01	5.57 [3.99, 7.77]	4.3e-24	133
1 year	0.00	12.27 [8.46, 17.79]	6.0e-40	57

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: E4_DM1NASCOMP – Type 1 diabetes with other specified/multiple/unspecified complications
GWS hits: 25

Survival analyses between endpoints

↥

Plot

before Type 1 diabetes with other specified/multiple/unspecified complications
after Type 1 diabetes with other specified/multiple/unspecified complications

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Type 1 diabetes with other specified/multiple/unspecified complications

↥